20 followers
RT @BreastOncPubMed: .@ESMO_Open Retrospective study (n=538) of second-line treatments after 1L ET ± CDK4/6i for HR+/HER2- mBC. Chemotherap…
RT @BreastOncPubMed: .@ESMO_Open Retrospective study (n=538) of second-line treatments after 1L ET ± CDK4/6i for HR+/HER2- mBC. Chemotherap…
.@ESMO_Open Retrospective study (n=538) of second-line treatments after 1L ET ± CDK4/6i for HR+/HER2- mBC. Chemotherapy efficacy reduced (HR 1.26, P=0.003) when exposed to CDK4/6i. PMID:40967066 https://t.co/cVQvPGjLDS